Editas Medicine

Editas Medicine is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts, developing durable, precision CRISPR-based gene editing medicines for people with serious diseases. The company works across in vivo and ex vivo approaches and holds foundational CRISPR/Cas9 and Cas12a intellectual property, advancing a pipeline that has included programs in sickle cell disease, beta-thalassemia and inherited retinal disorders. Editas Medicine trades on Nasdaq under the ticker EDIT and was surfaced in the API Evangelist network as a portfolio company of GV (Google Ventures). As a life-sciences research and therapeutics organization it publishes a corporate and investor-relations web presence rather than a public developer API, so this profile captures its identity, web properties, and probed domain-security posture.

Editas Medicine is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Editing, and CRISPR.

Editas Medicine’s developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyLife SciencesBiotechnologyGene EditingCRISPRGenomicsTherapeuticsPharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 10.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 1.0 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/editas-medicine: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: editas-medicine
name: Editas Medicine
description: Editas Medicine is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts, developing
  durable, precision CRISPR-based gene editing medicines for people with serious diseases. The company works across in vivo
  and ex vivo approaches and holds foundational CRISPR/Cas9 and Cas12a intellectual property, advancing a pipeline that has
  included programs in sickle cell disease, beta-thalassemia and inherited retinal disorders. Editas Medicine trades on Nasdaq
  under the ticker EDIT and was surfaced in the API Evangelist network as a portfolio company of GV (Google Ventures). As
  a life-sciences research and therapeutics organization it publishes a corporate and investor-relations web presence rather
  than a public developer API, so this profile captures its identity, web properties, and probed domain-security posture.
url: https://raw.githubusercontent.com/api-evangelist/editas-medicine/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.editasmedicine.com/wp-content/themes/sage/dist/images/logo-editas-gray_f449d648.svg
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Gene Editing
- CRISPR
- Genomics
- Therapeutics
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.editasmedicine.com
- type: Blog
  url: https://ir.editasmedicine.com/news-releases
- type: Support
  url: https://www.editasmedicine.com/contact/
- type: PrivacyPolicy
  url: https://www.editasmedicine.com/privacy-policy/
- type: TermsOfService
  url: https://www.editasmedicine.com/terms-of-use/
- type: DomainSecurity
  url: security/editas-medicine-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence